1
|
Paz-González R, Lourido L, Calamia V, Fernández-Puente P, Quaranta P, Picchi F, Blanco FJ, Ruiz-Romero C. An Atlas of the Knee Joint Proteins and Their Role in Osteoarthritis Defined by Literature Mining. Mol Cell Proteomics 2023; 22:100606. [PMID: 37356495 PMCID: PMC10393810 DOI: 10.1016/j.mcpro.2023.100606] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2023] [Revised: 06/14/2023] [Accepted: 06/18/2023] [Indexed: 06/27/2023] Open
Abstract
Osteoarthritis (OA) is the most prevalent rheumatic pathology. However, OA is not simply a process of wear and tear affecting articular cartilage but rather a disease of the entire joint. One of the most common locations of OA is the knee. Knee tissues have been studied using molecular strategies, generating a large amount of complex data. As one of the goals of the Rheumatic and Autoimmune Diseases initiative of the Human Proteome Project, we applied a text-mining strategy to publicly available literature to collect relevant information and generate a systematically organized overview of the proteins most closely related to the different knee components. To this end, the PubPular literature-mining software was employed to identify protein-topic relationships and extract the most frequently cited proteins associated with the different knee joint components and OA. The text-mining approach searched over eight million articles in PubMed up to November 2022. Proteins associated with the six most representative knee components (articular cartilage, subchondral bone, synovial membrane, synovial fluid, meniscus, and cruciate ligament) were retrieved and ranked by their relevance to the tissue and OA. Gene ontology analyses showed the biological functions of these proteins. This study provided a systematic and prioritized description of knee-component proteins most frequently cited as associated with OA. The study also explored the relationship of these proteins to OA and identified the processes most relevant to proper knee function and OA pathophysiology.
Collapse
Affiliation(s)
- Rocío Paz-González
- Grupo de Investigación de Reumatología (GIR) - Unidad de Proteómica, Instituto de Investigación Biomédica de A Coruña (INIBIC), Sergas, Complexo Hospitalario Universitario de A Coruña (CHUAC), A Coruña, Spain
| | - Lucía Lourido
- Grupo de Investigación de Reumatología (GIR) - Unidad de Proteómica, Instituto de Investigación Biomédica de A Coruña (INIBIC), Sergas, Complexo Hospitalario Universitario de A Coruña (CHUAC), A Coruña, Spain
| | - Valentina Calamia
- Grupo de Investigación de Reumatología (GIR) - Unidad de Proteómica, Instituto de Investigación Biomédica de A Coruña (INIBIC), Sergas, Complexo Hospitalario Universitario de A Coruña (CHUAC), A Coruña, Spain
| | - Patricia Fernández-Puente
- Departamento de Fisioterapia, Medicina y Ciencias Biomédicas, Grupo de Investigación de Reumatología y Salud (GIR-S), Centro Interdisciplinar de Química e Bioloxía (CICA), Universidade da Coruña (UDC), A Coruña, Spain
| | - Patricia Quaranta
- Grupo de Investigación de Reumatología (GIR) - Unidad de Proteómica, Instituto de Investigación Biomédica de A Coruña (INIBIC), Sergas, Complexo Hospitalario Universitario de A Coruña (CHUAC), A Coruña, Spain
| | - Florencia Picchi
- Grupo de Investigación de Reumatología (GIR) - Unidad de Proteómica, Instituto de Investigación Biomédica de A Coruña (INIBIC), Sergas, Complexo Hospitalario Universitario de A Coruña (CHUAC), A Coruña, Spain
| | - Francisco J Blanco
- Grupo de Investigación de Reumatología (GIR) - Unidad de Proteómica, Instituto de Investigación Biomédica de A Coruña (INIBIC), Sergas, Complexo Hospitalario Universitario de A Coruña (CHUAC), A Coruña, Spain; Departamento de Fisioterapia, Medicina y Ciencias Biomédicas, Grupo de Investigación de Reumatología y Salud (GIR-S), Centro Interdisciplinar de Química e Bioloxía (CICA), Universidade da Coruña (UDC), A Coruña, Spain.
| | - Cristina Ruiz-Romero
- Grupo de Investigación de Reumatología (GIR) - Unidad de Proteómica, Instituto de Investigación Biomédica de A Coruña (INIBIC), Sergas, Complexo Hospitalario Universitario de A Coruña (CHUAC), A Coruña, Spain; Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain.
| |
Collapse
|
2
|
Ruiz-Romero C, Fernández-Puente P, González L, Illiano A, Lourido L, Paz R, Quaranta P, Perez-Pampín E, González A, Blanco FJ, Calamia V. Association of the serological status of rheumatoid arthritis patients with two circulating protein biomarkers: A useful tool for precision medicine strategies. Front Med (Lausanne) 2022; 9:963540. [PMID: 36388911 PMCID: PMC9651940 DOI: 10.3389/fmed.2022.963540] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2022] [Accepted: 10/03/2022] [Indexed: 08/27/2023] Open
Abstract
Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation of the joints and presence of systemic autoantibodies, with a great clinical and molecular heterogeneity. Rheumatoid Factor (RF) and anti-citrullinated protein antibodies (ACPA) are routinely used for the diagnosis of RA. However, additional serological markers are needed to improve the clinical management of this disease, allowing for better patient stratification and the desirable application of precision medicine strategies. In the present study, we investigated those systemic molecular changes that are associated with the RF and ACPA status of RA patients. To achieve this objective, we followed a proteomic biomarker pipeline from the discovery phase to validation. First, we performed an iTRAQ-based quantitative proteomic experiment on serum samples from the RA cohort of the Hospital of Santiago de Compostela (CHUS). In this discovery phase, serum samples from the CHUS cohort were pooled according to their RF/ACPA status. Shotgun analysis revealed that, in comparison with the double negative group (RF-/ACPA-), the abundance of 12 proteins was altered in the RF+/ACPA+ pool, 16 in the RF+/ACPA- pool and 10 in the RF-/ACPA+ pool. Vitamin D binding protein and haptoglobin were the unique proteins increased in all the comparisons. For the verification phase, 80 samples from the same cohort were analyzed individually. To this end, we developed a Multiple Reaction Monitoring (MRM) method that was employed in a comprehensive targeted analysis with the aim of verifying the results obtained in the discovery phase. Thirty-one peptides belonging to 12 proteins associated with RF and/or ACPA status were quantified by MRM. In a final validation phase, the serum levels of alpha-1-acid glycoprotein 1 (A1AG1), haptoglobin (HPT) and retinol-binding protein 4 (RET4) were measured by immunoassays in the RA cohort of the Hospital of A Coruña (HUAC). The increase of two of these putative biomarkers in the double seropositive group was validated in 260 patients from this cohort (p = 0.009 A1AG1; p = 0.003 HPT). The increased level of A1AG1 showed association with RF rather than ACPA (p = 0.023), whereas HPT showed association with ACPA rather than RF (p = 0.013). Altogether, this study has allowed a further classification of the RA seropositive patients into two novel clusters: RF+A1AG+ and ACPA+HPT+. The determination of A1AG1 and HPT in serum would provide novel information useful for RA patient stratification, which could facilitate the effective implementation of personalized medicine in routine clinical practice.
Collapse
Affiliation(s)
- Cristina Ruiz-Romero
- Unidad de Proteómica, Grupo de Investigación de Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña (UDC), A Coruña, Spain
- Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain
| | - Patricia Fernández-Puente
- Centro de Investigaciones Científicas Avanzadas (CICA), Universidad de A Coruña (UDC), A Coruña, Spain
| | - Lucía González
- Unidad de Proteómica, Grupo de Investigación de Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña (UDC), A Coruña, Spain
| | - Anna Illiano
- CEINGE—Advanced Biotechnology, Naples, Italy
- Department of Chemical Sciences, University of Naples Federico II, Naples, Italy
| | - Lucía Lourido
- Unidad de Proteómica, Grupo de Investigación de Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña (UDC), A Coruña, Spain
| | - Rocío Paz
- Unidad de Proteómica, Grupo de Investigación de Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña (UDC), A Coruña, Spain
| | - Patricia Quaranta
- Unidad de Proteómica, Grupo de Investigación de Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña (UDC), A Coruña, Spain
| | - Eva Perez-Pampín
- Laboratorio de Investigación 10 and Rheumatology Unit, Instituto de Investigación Sanitaria (IDIS), Hospital Clínico Universitario de Santiago (CHUS), Santiago de Compostela, Spain
| | - Antonio González
- Laboratorio de Investigación 10 and Rheumatology Unit, Instituto de Investigación Sanitaria (IDIS), Hospital Clínico Universitario de Santiago (CHUS), Santiago de Compostela, Spain
| | - Francisco J. Blanco
- Unidad de Proteómica, Grupo de Investigación de Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña (UDC), A Coruña, Spain
- Grupo de Investigación de Reumatología y Salud (GIR-S), Departamento de Fisioterapia, Medicina y Ciencias Biomédicas, Facultad de Fisioterapia, Universidade da Coruña (UDC), A Coruña, Spain
| | - Valentina Calamia
- Unidad de Proteómica, Grupo de Investigación de Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña (UDC), A Coruña, Spain
| |
Collapse
|
3
|
Sánchez-Barrionuevo L, Mateos J, Fernández-Puente P, Begines P, Fernández-Bolaños JG, Gutiérrez G, Cánovas D, Mellado E. Identification of an acetyl esterase in the supernatant of the environmental strain Bacillus sp. HR21-6. Biochimie 2022; 198:48-59. [DOI: 10.1016/j.biochi.2022.03.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2021] [Revised: 02/22/2022] [Accepted: 03/14/2022] [Indexed: 11/02/2022]
|
4
|
Colomé N, Abian J, Aloria K, Arizmendi JM, Barceló-Batllori S, Braga-Lagache S, Burlet-Schiltz O, Carrascal M, Casal JI, Chicano-Gálvez E, Chiva C, Clemente LF, Elortza F, Estanyol JM, Fernandez-Irigoyen J, Fernández-Puente P, Fidalgo MJ, Froment C, Fuentes M, Fuentes-Almagro C, Gay M, Hainard A, Heller M, Hernández ML, Ibarrola N, Iloro I, Kieselbach T, Lario A, Locard-Paulet M, Marina-Ramírez A, Martín L, Morato-López E, Muñoz J, Navajas R, Odena MA, Odriozola L, de Oliveira E, Paradela A, Pasquarello C, de Los Rios V, Ruiz-Romero C, Sabidó E, Sánchez Del Pino M, Sancho J, Santamaría E, Schaeffer-Reiss C, Schneider J, de la Torre C, Valero ML, Vilaseca M, Wu S, Wu L, Ximénez de Embún P, Canals F, Corrales FJ. Multi-laboratory experiment PME11 for the standardization of phosphoproteome analysis. J Proteomics 2022; 251:104409. [PMID: 34758407 DOI: 10.1016/j.jprot.2021.104409] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2021] [Revised: 10/12/2021] [Accepted: 10/27/2021] [Indexed: 11/16/2022]
Abstract
Global analysis of protein phosphorylation by mass spectrometry proteomic techniques has emerged in the last decades as a powerful tool in biological and biomedical research. However, there are several factors that make the global study of the phosphoproteome more challenging than measuring non-modified proteins. The low stoichiometry of the phosphorylated species and the need to retrieve residue specific information require particular attention on sample preparation, data acquisition and processing to ensure reproducibility, qualitative and quantitative robustness and ample phosphoproteome coverage in phosphoproteomic workflows. Aiming to investigate the effect of different variables in the performance of proteome wide phosphoprotein analysis protocols, ProteoRed-ISCIII and EuPA launched the Proteomics Multicentric Experiment 11 (PME11). A reference sample consisting of a yeast protein extract spiked in with different amounts of a phosphomix standard (Sigma/Merck) was distributed to 31 laboratories around the globe. Thirty-six datasets from 23 laboratories were analyzed. Our results indicate the suitability of the PME11 reference sample to benchmark and optimize phosphoproteomics strategies, weighing the influence of different factors, as well as to rank intra and inter laboratory performance.
Collapse
Affiliation(s)
- Núria Colomé
- ProteoRed-ISCIII, Vall d'Hebron Institute of Oncology (VHIO), Barcelona 08035, Spain
| | - Joaquín Abian
- ProteoRed-ISCIII, Instituto de Investigaciones Biomédicas de Barcelona, IIBB-CSIC/IDIBAPS, 08036 Barcelona, Spain
| | - Kerman Aloria
- ProteoRed-ISCIII, Proteomics Core Facility-SGIKER, University of the Basque Country (UPV/EHU), Leioa, Spain
| | - Jesús M Arizmendi
- Department of Biochemistry and Molecular Biology, Faculty of Science and Technology, University of the Basque Country (UPV/EHU), Leioa, Spain
| | | | - Sophie Braga-Lagache
- Department for BioMedical Research (DBMR), Proteomics and Mass Spectrometry Core Facility, University of Bern, CH-3010 Bern, Switzerland
| | - Odile Burlet-Schiltz
- Proteomics and Mass Spectrometry of Biomolecules, Proteomics Infrastructure of Toulouse, Proteomics French Infrastructure, ProFI. Institut de Pharmacologie et Biologie Structurale (IPBS), Université de Toulouse, UPS, CNRS, Toulouse, France
| | - Montse Carrascal
- ProteoRed-ISCIII, Instituto de Investigaciones Biomédicas de Barcelona, IIBB-CSIC/IDIBAPS, 08036 Barcelona, Spain
| | - J Ignacio Casal
- ProteoRed-ISCIII, Centro de Investigaciones Biológicas-CSIC, Madrid 28040, Spain
| | - Eduard Chicano-Gálvez
- ProteoRed-ISCIII, Proteomics Unit, IMIBIC/UCO/HURS, IMIBIC Building Fl.3, 14004 Córdoba, Spain
| | - Cristina Chiva
- Proteomics Unit, Center for Genomics Regulation, Barcelona Institute of Science and Technology (BIST), Barcelona, Spain; ProteoRed ISCIII, Proteomics Unit, Universitat Pompeu Fabra, Barcelona, Spain
| | | | - Felix Elortza
- ProteoRed-ISCIII, CIC bioGUNE, Proteomics Platform, Basque Research & Technology Alliance (BRTA), CIBERehd,Bizkaia Science and Technology Park, 48160 Derio, Spain
| | - Josep M Estanyol
- ProteoRed-ISCIII, Scientific and Technological Centers (CCiTUB), University of Barcelona, 08036 Barcelona, Spain
| | - Joaquín Fernandez-Irigoyen
- Proteored-ISCIII. Proteomics Unit, Clinical Neuroproteomics Group, Navarrabiomed, Complejo Hospitalario de Navarra (CHN), Universidad Pública de Navarra (UPNA), IdiSNA, 31008 Pamplona, Spain
| | - Patricia Fernández-Puente
- Grupo de Investigación de Reumatología (GIR), Agrupación CICA-INIBIC, Universidad de A Coruña, A Coruña, Spain
| | - María José Fidalgo
- ProteoRed-ISCIII, Scientific and Technological Centers (CCiTUB), University of Barcelona, 08036 Barcelona, Spain
| | - Carine Froment
- Proteomics and Mass Spectrometry of Biomolecules, Proteomics Infrastructure of Toulouse, Proteomics French Infrastructure, ProFI. Institut de Pharmacologie et Biologie Structurale (IPBS), Université de Toulouse, UPS, CNRS, Toulouse, France
| | - Manuel Fuentes
- Department of Medicine and General Cytometry Service-Nucleus, Proteomics Unit, CIBERONC, Cancer Research Center (IBMCC/CSIC/USAL/IBSAL), Universidad de Salamanca, Spain
| | - Carlos Fuentes-Almagro
- Proteomics Unit, SCAI, University of Córdoba, Ramón y Cajal Building, Rabanales Campus, 14071, Córdoba, Spain
| | - Marina Gay
- ProteoRed-ISCIII, Institute for Research in Biomedicine (IRB Barcelona), BIST (The Barcelona Institute of Science and Technology), Baldiri i Reixac 10, 08028 Barcelona, Spain
| | | | - Manfred Heller
- Department for BioMedical Research (DBMR), Proteomics and Mass Spectrometry Core Facility, University of Bern, CH-3010 Bern, Switzerland
| | | | - Nieves Ibarrola
- ProteoRed-ISCIII, Proteomics Unit. Cancer Research Center (IBMCC/CSIC/USAL/IBSAL), Universidad de Salamanca-CSIC, Salamanca, Spain
| | - Ibon Iloro
- ProteoRed-ISCIII, CIC bioGUNE, Proteomics Platform, Basque Research & Technology Alliance (BRTA), CIBERehd,Bizkaia Science and Technology Park, 48160 Derio, Spain
| | | | | | - Marie Locard-Paulet
- Proteomics and Mass Spectrometry of Biomolecules, Proteomics Infrastructure of Toulouse, Proteomics French Infrastructure, ProFI. Institut de Pharmacologie et Biologie Structurale (IPBS), Université de Toulouse, UPS, CNRS, Toulouse, France
| | | | - Luna Martín
- ProteoRed-ISCIII, Vall d'Hebron Institute of Oncology (VHIO), Barcelona 08035, Spain
| | | | - Javier Muñoz
- ProteoRed-ISCIII, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain
| | - Rosana Navajas
- ProteoRed-ISCIII, Centro Nacional de Biotecnologia (CSIC), 28049, Madrid, Spain
| | - M Antonia Odena
- ProteoRed-ISCIII, Proteomics Platform, Barcelona Science Park, 08028, Barcelona, Spain
| | - Leticia Odriozola
- ProteoRed-ISCIII, CIMA, University of Navarra, 31008, Pamplona, Spain
| | - Eliandre de Oliveira
- ProteoRed-ISCIII, Proteomics Platform, Barcelona Science Park, 08028, Barcelona, Spain
| | - Alberto Paradela
- ProteoRed-ISCIII, Centro Nacional de Biotecnologia (CSIC), 28049, Madrid, Spain
| | | | - Vivian de Los Rios
- ProteoRed-ISCIII, Centro de Investigaciones Biológicas-CSIC, Madrid 28040, Spain
| | - Cristina Ruiz-Romero
- Grupo de Investigación de Reumatología (GIR) - ProteoRed-ISCIII, Unidad de Proteómica, INIBIC-Complejo Hospitalario Universitario de A Coruña, SERGAS, A Coruña, Spain
| | - Eduard Sabidó
- Proteomics Unit, Center for Genomics Regulation, Barcelona Institute of Science and Technology (BIST), Barcelona, Spain; ProteoRed ISCIII, Proteomics Unit, Universitat Pompeu Fabra, Barcelona, Spain
| | - Manuel Sánchez Del Pino
- Biotechnology and Biomedicine Interdisciplinary Research Unit (ERI BIOTECMED), University of Valencia, 46100 Burjassot, Spain
| | - Jaime Sancho
- ProteoRed-ISCIII, IPBLN -CSIC, 18016 Granada, Spain
| | - Enrique Santamaría
- Proteored-ISCIII. Proteomics Unit, Clinical Neuroproteomics Group, Navarrabiomed, Complejo Hospitalario de Navarra (CHN), Universidad Pública de Navarra (UPNA), IdiSNA, 31008 Pamplona, Spain
| | - Christine Schaeffer-Reiss
- Laboratoire de Spectrométrie de Masse BioOrganique, Université de Strasbourg, CNRS, IPHC UMR 7178, 67000, Strasbourg, France
| | - Justine Schneider
- Laboratoire de Spectrométrie de Masse BioOrganique, Université de Strasbourg, CNRS, IPHC UMR 7178, 67000, Strasbourg, France
| | - Carolina de la Torre
- ProteoRed-ISCIII, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain
| | - M Luz Valero
- ProteoRed-ISCIII, Proteomics Unit, Central Service for Experimental Research (SCSIE), University of Valencia, 46100, Burjassot, Spain
| | - Marta Vilaseca
- ProteoRed-ISCIII, Institute for Research in Biomedicine (IRB Barcelona), BIST (The Barcelona Institute of Science and Technology), Baldiri i Reixac 10, 08028 Barcelona, Spain
| | - Shuai Wu
- Agilent Technologies, Inc., Santa Clara, CA 95051, USA
| | - Linfeng Wu
- Agilent Technologies, Inc., Santa Clara, CA 95051, USA
| | | | - Francesc Canals
- ProteoRed-ISCIII, Vall d'Hebron Institute of Oncology (VHIO), Barcelona 08035, Spain.
| | - Fernando J Corrales
- ProteoRed-ISCIII, Centro Nacional de Biotecnologia (CSIC), 28049, Madrid, Spain; ProteoRed-ISCIII, CIMA, University of Navarra, 31008, Pamplona, Spain.
| | -
- ProteoRed-ISCIII, Centro Nacional de Biotecnologia (CSIC), 28049, Madrid, Spain; ProteoRed-ISCIII-PRB3, Spanish Proteomics Networked Platform, Centro Nacional de Biotecnología (CSIC), 28049, Madrid, Spain
| | -
- ProteoRed-ISCIII, Centro Nacional de Biotecnologia (CSIC), 28049, Madrid, Spain; European Proteomics Association, Standardization Initiative, , Centro Nacional de Biotecnología (CSIC), 28049, Madrid, Spain
| |
Collapse
|
5
|
Fernández-Puente P, González-Rodríguez L, Calamia V, Picchi F, Lourido L, Camacho-Encina M, Oreiro N, Rocha B, Paz-González R, Marina A, García C, Blanco FJ, Ruiz-Romero C. Analysis of Endogenous Peptides Released from Osteoarthritic Cartilage Unravels Novel Pathogenic Markers. Mol Cell Proteomics 2019; 18:2018-2028. [PMID: 31352363 PMCID: PMC6773562 DOI: 10.1074/mcp.ra119.001554] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2019] [Revised: 07/08/2019] [Indexed: 12/31/2022] Open
Abstract
Osteoarthritis (OA) is a pathology characterized by the loss of articular cartilage. In this study, we performed a peptidomic strategy to identify endogenous peptides (neopeptides) that are released from human osteoarthritic tissue, which may serve as disease markers. With this aim, secretomes of osteoarthritic and healthy articular cartilages obtained from knee and hip were analyzed by shotgun peptidomics. This discovery step led to the identification of 1175 different peptides, corresponding to 101 proteins, as products of the physiological or pathological turnover of cartilage extracellular matrix. Then, a targeted multiple reaction monitoring-mass spectrometry method was developed to quantify the panel of best marker candidates on a larger set of samples (n = 62). Statistical analyses were performed to evaluate the significance of the observed differences and the ability of the neopeptides to classify the tissue. Eight of them were differentially abundant in the media from wounded zones of OA cartilage compared with the healthy tissue (p < 0.05). Three neopeptides belonging to Clusterin and one from Cartilage Oligomeric Matrix Protein showed a disease-dependent decrease specifically in hip OA, whereas two from Prolargin (PRELP) and one from Cartilage Intermediate Layer Protein 1 were significantly increased in samples from knee OA. The release of one peptide from PRELP showed the best metrics for tissue classification (AUC = 0.834). The present study reveals specific neopeptides that are differentially released from knee or hip human osteoarthritic cartilage compared with healthy tissue. This evidences the intervention of characteristic pathogenic pathways in OA and provides a novel panel of peptidic candidates for biomarker development.
Collapse
MESH Headings
- Aged
- Aged, 80 and over
- Biomarkers/metabolism
- Cartilage, Articular/cytology
- Cartilage, Articular/metabolism
- Cartilage, Articular/pathology
- Case-Control Studies
- Cells, Cultured
- Chromatography, Liquid
- Culture Media, Conditioned/chemistry
- Extracellular Matrix/metabolism
- Female
- Humans
- Male
- Organ Specificity
- Osteoarthritis, Hip/metabolism
- Osteoarthritis, Hip/pathology
- Osteoarthritis, Knee/metabolism
- Osteoarthritis, Knee/pathology
- Peptides/metabolism
- Proteomics/methods
- Tandem Mass Spectrometry
Collapse
Affiliation(s)
- Patricia Fernández-Puente
- Proteomics Unit-PBR2-ProteoRed/ISCIII, Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), SERGAS. As Xubias, 84, 15006 A Coruña, Spain.; Agrupación Estratégica CICA - INIBIC, Universidade da Coruña, 15071 A Coruña, Spain
| | - Lucía González-Rodríguez
- Proteomics Unit-PBR2-ProteoRed/ISCIII, Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), SERGAS. As Xubias, 84, 15006 A Coruña, Spain
| | - Valentina Calamia
- Proteomics Unit-PBR2-ProteoRed/ISCIII, Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), SERGAS. As Xubias, 84, 15006 A Coruña, Spain
| | - Florencia Picchi
- Proteomics Unit-PBR2-ProteoRed/ISCIII, Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), SERGAS. As Xubias, 84, 15006 A Coruña, Spain
| | - Lucía Lourido
- Proteomics Unit-PBR2-ProteoRed/ISCIII, Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), SERGAS. As Xubias, 84, 15006 A Coruña, Spain
| | - María Camacho-Encina
- Proteomics Unit-PBR2-ProteoRed/ISCIII, Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), SERGAS. As Xubias, 84, 15006 A Coruña, Spain
| | - Natividad Oreiro
- Proteomics Unit-PBR2-ProteoRed/ISCIII, Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), SERGAS. As Xubias, 84, 15006 A Coruña, Spain
| | - Beatriz Rocha
- Proteomics Unit-PBR2-ProteoRed/ISCIII, Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), SERGAS. As Xubias, 84, 15006 A Coruña, Spain
| | - Rocío Paz-González
- Proteomics Unit-PBR2-ProteoRed/ISCIII, Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), SERGAS. As Xubias, 84, 15006 A Coruña, Spain
| | - Anabel Marina
- Centro de Biología Molecular Severo Ochoa, CSIC. Nicolás Cabrera, 1, 28049 Madrid, Spain
| | - Carlos García
- Centro de Biología Molecular Severo Ochoa, CSIC. Nicolás Cabrera, 1, 28049 Madrid, Spain
| | - Francisco J Blanco
- Proteomics Unit-PBR2-ProteoRed/ISCIII, Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), SERGAS. As Xubias, 84, 15006 A Coruña, Spain.; Departamento de Medicina, Fisioterapia y Ciencias Biomédicas. Universidade da Coruña, 15006 A Coruña, Spain.; RIER-RED de Inflamación y Enfermedades Reumáticas, INIBIC-CHUAC, As Xubias 84, 15006 A Coruña, Spain.
| | - Cristina Ruiz-Romero
- Proteomics Unit-PBR2-ProteoRed/ISCIII, Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), SERGAS. As Xubias, 84, 15006 A Coruña, Spain.; CIBER-BBN Instituto de Salud Carlos III INIBIC-CHUAC As Xubias 84, 15006 A Coruna, Spain.
| |
Collapse
|
6
|
Blanco FJ, Camacho-Encina M, González-Rodríguez L, Rego-Pérez I, Mateos J, Fernández-Puente P, Lourido L, Rocha B, Picchi F, Silva-Díaz MT, Herrero M, Martínez H, Verges J, Ruiz-Romero C, Calamia V. Predictive modeling of therapeutic response to chondroitin sulfate/glucosamine hydrochloride in knee osteoarthritis. Ther Adv Chronic Dis 2019; 10:2040622319870013. [PMID: 31489155 PMCID: PMC6710680 DOI: 10.1177/2040622319870013] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2019] [Accepted: 07/17/2019] [Indexed: 11/17/2022] Open
Abstract
Background In the present study, we explored potential protein biomarkers useful to predict the therapeutic response of knee osteoarthritis (KOA) patients treated with pharmaceutical grade Chondroitin sulfate/Glucosamine hydrochloride (CS+GH; Droglican, Bioiberica), in order to optimize therapeutic outcomes. Methods A shotgun proteomic analysis by iTRAQ labelling and liquid chromatography-mass spectrometry (LC-MS/MS) was performed using sera from 40 patients enrolled in the Multicentre Osteoarthritis interVEntion trial with Sysadoa (MOVES). The panel of proteins potentially useful to predict KOA patient's response was clinically validated in the whole MOVES cohort at baseline (n = 506) using commercially available enzyme-linked immunosorbent assays kits. Logistic regression models and receiver-operating-characteristics (ROC) curves were used to analyze the contribution of these proteins to our prediction models of symptomatic drug response in KOA. Results In the discovery phase of the study, a panel of six putative predictive biomarkers of response to CS+GH (APOA2, APOA4, APOH, ITIH1, C4BPa and ORM2) were identified by shotgun proteomics. Data are available via ProteomeXchange with identifier PXD012444. In the verification phase, the panel was verified in a larger set of KOA patients (n = 262). Finally, ITIH1 and ORM2 were qualified by a blind test in the whole MOVES cohort at baseline. The combination of these biomarkers with clinical variables predict the patients' response to CS+GH with a specificity of 79.5% and a sensitivity of 77.1%. Conclusions Combining clinical and analytical parameters, we identified one biomarker that could accurately predict KOA patients' response to CS+GH treatment. Its use would allow an increase in response rates and safety for the patients suffering KOA.
Collapse
Affiliation(s)
- Francisco J Blanco
- Unidad de Proteómica-Grupo de Investigación de Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña, Spain
| | - María Camacho-Encina
- Unidad de Proteómica-Grupo de Investigación de Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña, Spain
| | - Lucía González-Rodríguez
- Unidad de Proteómica-Grupo de Investigación de Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña, Spain
| | - Ignacio Rego-Pérez
- Unidad de Genómica-Grupo de Investigación de Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña, Spain
| | - Jesús Mateos
- Unidad de Proteómica-Grupo de Investigación de Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña, Spain
| | - Patricia Fernández-Puente
- Unidad de Proteómica-Grupo de Investigación de Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña, Spain
| | - Lucía Lourido
- Unidad de Proteómica-Grupo de Investigación de Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña, Spain
| | - Beatriz Rocha
- Unidad de Proteómica-Grupo de Investigación de Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña, Spain
| | - Florencia Picchi
- Unidad de Proteómica-Grupo de Investigación de Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña, Spain
| | - María T Silva-Díaz
- Servicio de Reumatología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña, Spain
| | | | | | | | - Cristina Ruiz-Romero
- Unidad de Proteómica-Grupo de Investigación de Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña, Spain
| | - Valentina Calamia
- Grupo de Investigación de Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña, Spain
| |
Collapse
|
7
|
|
8
|
Pérez A, Merino M, Rumbo-Feal S, Álvarez-Fraga L, Vallejo JA, Beceiro A, Ohneck EJ, Mateos J, Fernández-Puente P, Actis LA, Poza M, Bou G. The FhaB/FhaC two-partner secretion system is involved in adhesion of Acinetobacter baumannii AbH12O-A2 strain. Virulence 2016; 8:959-974. [PMID: 27858524 DOI: 10.1080/21505594.2016.1262313] [Citation(s) in RCA: 42] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
Acinetobacter baumannii is a hospital-acquired pathogen that shows an extraordinary capacity to stay in the hospital environment. Adherence of the bacteria to eukaryotic cells or to abiotic surfaces is the first step for establishing an infection. The A. baumannii strain AbH12O-A2 showed an exceptional ability to adhere to A549 epithelial cells. The AbFhaB/FhaC 2-partner secretion (TPS) system involved in adhesion was discovered after the screening of the recently determined A. baumannii AbH12O-A2 strain genome (CP009534.1). The AbFhaB is a large exoprotein which transport to the bacterial surface is mediated by the AbFhaC protein. In the present study, the role of this TPS system in the AbH12O-A2 adherence phenotype was investigated. The functional inactivation of this 2-partner secretion system was addressed by analyzing the outer membrane vesicles (OMV) proteomic profile from the wild-type strain and its derivative mutant AbH12O-A2ΔfhaC demonstrating that AbFhaB is no longer detected in the absence of AbFhaC. Scanning electron microscopy (SEM) and adhesion experiments demonstrated that inactivation of the AbFhaB/FhaC system significantly decreases bacterial attachment to A549 alveolar epithelial cells. Moreover, it has been demonstrated that this 2-partner secretion system is involved in fibronectin-mediated adherence of the A. baumannii AbH12O-A2 isolate. Finally, we report that the AbFhaB/FhaC system is involved in virulence when tested using invertebrate and vertebrate hosts. These data suggest the potential role that this AbFhaB/FhaC secretion system could play in the pathobiology of A. baumannii.
Collapse
Affiliation(s)
- A Pérez
- a Departamento de Microbiología , Instituto de Investigación Biomédica (INIBIC), Complejo Hospitalario Universitario (CHUAC), Universidad da Coruña (UDC) , A Coruña , Spain.,b Departamento de Microbiología y Parasitología , Universidad de Santiago de Compostela (USC) , Santiago de Compostela , Spain.,c Department of Microbiology , Miami University , Oxford , OH , USA
| | - M Merino
- a Departamento de Microbiología , Instituto de Investigación Biomédica (INIBIC), Complejo Hospitalario Universitario (CHUAC), Universidad da Coruña (UDC) , A Coruña , Spain
| | - S Rumbo-Feal
- a Departamento de Microbiología , Instituto de Investigación Biomédica (INIBIC), Complejo Hospitalario Universitario (CHUAC), Universidad da Coruña (UDC) , A Coruña , Spain
| | - L Álvarez-Fraga
- a Departamento de Microbiología , Instituto de Investigación Biomédica (INIBIC), Complejo Hospitalario Universitario (CHUAC), Universidad da Coruña (UDC) , A Coruña , Spain
| | - J A Vallejo
- a Departamento de Microbiología , Instituto de Investigación Biomédica (INIBIC), Complejo Hospitalario Universitario (CHUAC), Universidad da Coruña (UDC) , A Coruña , Spain
| | - A Beceiro
- a Departamento de Microbiología , Instituto de Investigación Biomédica (INIBIC), Complejo Hospitalario Universitario (CHUAC), Universidad da Coruña (UDC) , A Coruña , Spain
| | - E J Ohneck
- c Department of Microbiology , Miami University , Oxford , OH , USA
| | - J Mateos
- d Grupo de Proteómica-ProteoRed/Plataforma PBR2-ISCIII, Servicio de Reumatología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complejo Hospitalario Universitario de A Coruña (CHUAC), Universidade da Coruña (UDC) , A Coruña , Spain.,e Marine Research Institute, Consejo Superior de Investigaciones Científicas (CSIC) , Vigo , Spain
| | - P Fernández-Puente
- d Grupo de Proteómica-ProteoRed/Plataforma PBR2-ISCIII, Servicio de Reumatología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complejo Hospitalario Universitario de A Coruña (CHUAC), Universidade da Coruña (UDC) , A Coruña , Spain
| | - L A Actis
- c Department of Microbiology , Miami University , Oxford , OH , USA
| | - M Poza
- a Departamento de Microbiología , Instituto de Investigación Biomédica (INIBIC), Complejo Hospitalario Universitario (CHUAC), Universidad da Coruña (UDC) , A Coruña , Spain
| | - G Bou
- a Departamento de Microbiología , Instituto de Investigación Biomédica (INIBIC), Complejo Hospitalario Universitario (CHUAC), Universidad da Coruña (UDC) , A Coruña , Spain
| |
Collapse
|
9
|
Calamia V, Mateo J, Fernández-Puente P, Lourido L, Camacho M, Oreiro N, Raga A, Acasuso M, Herrero M, Martinez H, Verges J, Ruiz-Romero C, Blanco F. SAT0447 Identification of Predictive Biomarkers of Therapeutic Response in Knee OA: The Moves Study. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.3403] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
10
|
Abstract
Osteoarthritis is the most common rheumatic pathology and one of the leading causes of disability worldwide. It is a very complex disease whose etiopathogenesis is not fully understood. Furthermore, there are serious limitations for its management, since it lacks specific and sensitive biomarkers for early diagnosis, prognosis and therapeutic monitoring. Proteomic approaches performed in the last few decades have contributed to the knowledge on the molecular mechanisms that participate in this pathology and they have also led to interesting panels of putative biomarker candidates. In the next few years, further efforts should be made for translating these findings into the clinical routines. It is expected that targeted proteomics strategies will be highly valuable for the verification and qualification of biomarkers of osteoarthritis.
Collapse
Affiliation(s)
- Cristina Ruiz-Romero
- Rheumatology Division, ProteoRed/ISCIII Proteomics Group, INIBIC - Hospital Universitario de A Coruña, 15006 A Coruña, Spain
| | | | | | | |
Collapse
|
11
|
Lourido L, Calamia V, Fernández-Puente P, Mateos J, Oreiro N, Blanco FJ, Ruiz-Romero C. Secretome analysis of human articular chondrocytes unravels catabolic effects of nicotine on the joint. Proteomics Clin Appl 2015; 10:671-80. [DOI: 10.1002/prca.201400186] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2014] [Revised: 03/24/2015] [Accepted: 04/23/2015] [Indexed: 11/06/2022]
Affiliation(s)
- Lucía Lourido
- Proteomics Group-PBR2-ProteoRed/ISCIII; Rheumatology Division, Instituto de Investigación Biomédica de A Coruña (INIBIC); Complexo Hospitalario Universitario de A Coruña (CHUAC); Sergas, Universidade da Coruña (UDC); A Coruña Spain
| | - Valentina Calamia
- Proteomics Group-PBR2-ProteoRed/ISCIII; Rheumatology Division, Instituto de Investigación Biomédica de A Coruña (INIBIC); Complexo Hospitalario Universitario de A Coruña (CHUAC); Sergas, Universidade da Coruña (UDC); A Coruña Spain
| | - Patricia Fernández-Puente
- Proteomics Group-PBR2-ProteoRed/ISCIII; Rheumatology Division, Instituto de Investigación Biomédica de A Coruña (INIBIC); Complexo Hospitalario Universitario de A Coruña (CHUAC); Sergas, Universidade da Coruña (UDC); A Coruña Spain
| | - Jesús Mateos
- Proteomics Group-PBR2-ProteoRed/ISCIII; Rheumatology Division, Instituto de Investigación Biomédica de A Coruña (INIBIC); Complexo Hospitalario Universitario de A Coruña (CHUAC); Sergas, Universidade da Coruña (UDC); A Coruña Spain
| | - Natividad Oreiro
- Proteomics Group-PBR2-ProteoRed/ISCIII; Rheumatology Division, Instituto de Investigación Biomédica de A Coruña (INIBIC); Complexo Hospitalario Universitario de A Coruña (CHUAC); Sergas, Universidade da Coruña (UDC); A Coruña Spain
| | - Francisco J. Blanco
- Proteomics Group-PBR2-ProteoRed/ISCIII; Rheumatology Division, Instituto de Investigación Biomédica de A Coruña (INIBIC); Complexo Hospitalario Universitario de A Coruña (CHUAC); Sergas, Universidade da Coruña (UDC); A Coruña Spain
- RIER-RED de Inflamación y Enfermedades Reumáticas; Instituto de Investigación Biomédica de A Coruña (INIBIC); Complexo Hospitalario Universitario de A Coruña (CHUAC); A Coruña Spain
| | - Cristina Ruiz-Romero
- Proteomics Group-PBR2-ProteoRed/ISCIII; Rheumatology Division, Instituto de Investigación Biomédica de A Coruña (INIBIC); Complexo Hospitalario Universitario de A Coruña (CHUAC); Sergas, Universidade da Coruña (UDC); A Coruña Spain
- CIBER-BBN Instituto de Salud Carlos III; Instituto de Investigación Biomédica de A Coruña (INIBIC); Complexo Hospitalario Universitario de A Coruña (CHUAC); A Coruña Spain
| |
Collapse
|
12
|
Mateos J, Landeira-Abia A, Fafián-Labora JA, Fernández-Pernas P, Lesende-Rodríguez I, Fernández-Puente P, Fernández-Moreno M, Delmiro A, Martín MA, Blanco FJ, Arufe MC. iTRAQ-based analysis of progerin expression reveals mitochondrial dysfunction, reactive oxygen species accumulation and altered proteostasis. Stem Cell Res Ther 2015; 6:119. [PMID: 26066325 PMCID: PMC4487579 DOI: 10.1186/s13287-015-0110-5] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2014] [Revised: 10/14/2014] [Accepted: 06/04/2015] [Indexed: 02/08/2023] Open
Abstract
INTRODUCTION Nuclear accumulation of a mutant form of the nuclear protein Lamin-A, called Progerin (PG) or Lamin AΔ50, occurs in Hutchinson-Gilford Progeria Syndrome (HGPS) or Progeria, an accelerated aging disease. One of the main symptoms of this genetic disorder is a loss of sub-cutaneous fat due to a dramatic lipodystrophy. METHODS We stably induced the expression of human PG and GFP -Green Fluorescent Protein- as control in 3T3L1 cells using a lentiviral system to study the effect of PG expression in the differentiation capacity of this cell line, one of the most used adipogenic models. Quantitative proteomics (iTRAQ) was done to study the effect of the PG accumulation. Several of the modulated proteins were validated by immunoblotting and real-time PCR. Mitochondrial function was analyzed by measurement of a) the mitochondrial basal activity, b) the superoxide anion production and c) the individual efficiency of the different complex of the respiratory chain. RESULTS We found that over-expression PG by lentiviral gene delivery leads to a decrease in the proliferation rate and to defects in adipogenic capacity when compared to the control. Quantitative proteomics analysis showed 181 proteins significantly (p<0.05) modulated in PG-expressing preadipocytes. Mitochondrial function is impaired in PG-expressing cells. Specifically, we have detected an increase in the activity of the complex I and an overproduction of Superoxide anion. Incubation with Reactive Oxygen Species (ROS) scavenger agents drives to a decrease in autophagic proteolysis as revealed by LC3-II/LC3-I ratio. CONCLUSION PG expression in 3T3L1 cells promotes changes in several Biological Processes, including structure of cytoskeleton, lipid metabolism, calcium regulation, translation, protein folding and energy generation by the mitochondria. Our data strengthen the contribution of ROS accumulation to the premature aging phenotype and establish a link between mitochondrial dysfunction and loss of proteostasis in HGPS.
Collapse
Affiliation(s)
- Jesús Mateos
- Grupo de Proteómica-ProteoRed/Plataforma PBR2-ISCIII, Servicio de Reumatología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña, As Xubias, 15006, A Coruña, Spain.
| | - Arancha Landeira-Abia
- Grupo de Proteómica-ProteoRed/Plataforma PBR2-ISCIII, Servicio de Reumatología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña, As Xubias, 15006, A Coruña, Spain.
| | - Juan Antonio Fafián-Labora
- Cellular Therapy and Medicine Regenerative Group, Department of Medicine, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña, As Xubias, 15006, A Coruña, Spain.
| | - Pablo Fernández-Pernas
- Cellular Therapy and Medicine Regenerative Group, Department of Medicine, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña, As Xubias, 15006, A Coruña, Spain.
- Rheumatology Division, CIBER-BBN/ISCII, Instituto de Investigación Biomédica de A Coruña INIBIC-Hospital Universitario A Coruña, 15006, A Coruña, Spain.
| | - Iván Lesende-Rodríguez
- Cellular Therapy and Medicine Regenerative Group, Department of Medicine, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña, As Xubias, 15006, A Coruña, Spain.
| | - Patricia Fernández-Puente
- Grupo de Proteómica-ProteoRed/Plataforma PBR2-ISCIII, Servicio de Reumatología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña, As Xubias, 15006, A Coruña, Spain.
| | - Mercedes Fernández-Moreno
- Rheumatology Division, CIBER-BBN/ISCII, Instituto de Investigación Biomédica de A Coruña INIBIC-Hospital Universitario A Coruña, 15006, A Coruña, Spain.
- Grupo de Genómica, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña, As Xubias, 15006, A Coruña, Spain.
| | - Aitor Delmiro
- Laboratorio de Enfermedades Mitocondriales, Instituto de Investigación Hospital 12 de Octubre (i + 12), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), U723, Madrid, E-28041, Spain.
| | - Miguel A Martín
- Laboratorio de Enfermedades Mitocondriales, Instituto de Investigación Hospital 12 de Octubre (i + 12), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), U723, Madrid, E-28041, Spain.
| | - Francisco J Blanco
- Grupo de Proteómica-ProteoRed/Plataforma PBR2-ISCIII, Servicio de Reumatología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña, As Xubias, 15006, A Coruña, Spain.
- Rheumatology Division, CIBER-BBN/ISCII, Instituto de Investigación Biomédica de A Coruña INIBIC-Hospital Universitario A Coruña, 15006, A Coruña, Spain.
| | - María C Arufe
- Cellular Therapy and Medicine Regenerative Group, Department of Medicine, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña, As Xubias, 15006, A Coruña, Spain.
- Rheumatology Division, CIBER-BBN/ISCII, Instituto de Investigación Biomédica de A Coruña INIBIC-Hospital Universitario A Coruña, 15006, A Coruña, Spain.
| |
Collapse
|
13
|
Mateos J, Fernández-Puente P, Relaño S, Rego-Pérez I, Oreiro N, Fernández-Lόpez C, Ruiz-Romero C, Blanco-García F. AB0856 Quantitative Proteomics (Itraq) Reveals Putative Biomarkers in Pre-Radiological Osteoarthritis. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.3345] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
14
|
Ruiz-Romero C, Lourido L, Calamia V, Fernández-Puente P, Mateos J, Rocha B, Fernández-Costa C, Fernández-Lόpez C, Oreiro N, Blanco F. AB0090 Discovery of Early Biomarkers Specific of Hip or Knee Osteoarthritis by Quantitative Proteomic Profiling of Human Articular Cartilage Degradation. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.4007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
15
|
Gago-Fuentes R, Fernández-Puente P, Megias D, Carpintero-Fernández P, Mateos J, Acea B, Fonseca E, Blanco FJ, Mayan MD. Proteomic Analysis of Connexin 43 Reveals Novel Interactors Related to Osteoarthritis. Mol Cell Proteomics 2015; 14:1831-45. [PMID: 25903580 DOI: 10.1074/mcp.m115.050211] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2015] [Indexed: 11/06/2022] Open
Abstract
We have previously reported that articular chondrocytes in tissue contain long cytoplasmic arms that physically connect two distant cells. Cell-to-cell communication occurs through connexin channels termed Gap Junction (GJ) channels, which achieve direct cellular communication by allowing the intercellular exchange of ions, small RNAs, nutrients, and second messengers. The Cx43 protein is overexpressed in several human diseases and inflammation processes and in articular cartilage from patients with osteoarthritis (OA). An increase in the level of Cx43 is known to alter gene expression, cell signaling, growth, and cell proliferation. The interaction of proteins with the C-terminal tail of connexin 43 (Cx43) directly modulates GJ-dependent and -independent functions. Here, we describe the isolation of Cx43 complexes using mild extraction conditions and immunoaffinity purification. Cx43 complexes were extracted from human primary articular chondrocytes isolated from healthy donors and patients with OA. The proteomic content of the native complexes was determined using LC-MS/MS, and protein associations with Cx43 were validated using Western blot and immunolocalization experiments. We identified >100 Cx43-associated proteins including previously uncharacterized proteins related to nucleolar functions, RNA transport, and translation. We also identified several proteins involved in human diseases, cartilage structure, and OA as novel functional Cx43 interactors, which emphasized the importance of Cx43 in the normal physiology and structural and functional integrity of chondrocytes and articular cartilage. Gene Ontology (GO) terms of the proteins identified in the OA samples showed an enrichment of Cx43-interactors related to cell adhesion, calmodulin binding, the nucleolus, and the cytoskeleton in OA samples compared with healthy samples. However, the mitochondrial proteins SOD2 and ATP5J2 were identified only in samples from healthy donors. The identification of Cx43 interactors will provide clues to the functions of Cx43 in human cells and its roles in the development of several diseases, including OA.
Collapse
Affiliation(s)
- Raquel Gago-Fuentes
- From the ‡CellCOM Research Group. Instituto de Investigación Biomédica A Coruña (INIBIC), XXIAC, University of A Coruña. Xubias de Arriba 84, 15006 A Coruña, Spain
| | - Patricia Fernández-Puente
- §Rheumatology Division, ProteoRed/ISCIII, Proteomics Group, Instituto de Investigación Biomédica A Coruña (INIBIC), XXIAC. University of A Coruña. Xubias de Arriba 84, 15006 A Coruña, Spain; ¶Rheumatology Division, CIBER-BBN/ISCIII, Instituto de Investigación Biomédica A Coruña (INIBIC), XXIAC. University of A Coruña. Xubias de Arriba 84, 15006 A Coruña, Spain
| | - Diego Megias
- ‖Confocal Microscopy Core Unit. Centro Nacional de Investigaciones Oncológicas (CNIO), 28029, Madrid, Spain
| | - Paula Carpintero-Fernández
- From the ‡CellCOM Research Group. Instituto de Investigación Biomédica A Coruña (INIBIC), XXIAC, University of A Coruña. Xubias de Arriba 84, 15006 A Coruña, Spain
| | - Jesus Mateos
- §Rheumatology Division, ProteoRed/ISCIII, Proteomics Group, Instituto de Investigación Biomédica A Coruña (INIBIC), XXIAC. University of A Coruña. Xubias de Arriba 84, 15006 A Coruña, Spain; ¶Rheumatology Division, CIBER-BBN/ISCIII, Instituto de Investigación Biomédica A Coruña (INIBIC), XXIAC. University of A Coruña. Xubias de Arriba 84, 15006 A Coruña, Spain
| | - Benigno Acea
- From the ‡CellCOM Research Group. Instituto de Investigación Biomédica A Coruña (INIBIC), XXIAC, University of A Coruña. Xubias de Arriba 84, 15006 A Coruña, Spain
| | - Eduardo Fonseca
- From the ‡CellCOM Research Group. Instituto de Investigación Biomédica A Coruña (INIBIC), XXIAC, University of A Coruña. Xubias de Arriba 84, 15006 A Coruña, Spain
| | - Francisco Javier Blanco
- §Rheumatology Division, ProteoRed/ISCIII, Proteomics Group, Instituto de Investigación Biomédica A Coruña (INIBIC), XXIAC. University of A Coruña. Xubias de Arriba 84, 15006 A Coruña, Spain; ¶Rheumatology Division, CIBER-BBN/ISCIII, Instituto de Investigación Biomédica A Coruña (INIBIC), XXIAC. University of A Coruña. Xubias de Arriba 84, 15006 A Coruña, Spain
| | - Maria Dolores Mayan
- From the ‡CellCOM Research Group. Instituto de Investigación Biomédica A Coruña (INIBIC), XXIAC, University of A Coruña. Xubias de Arriba 84, 15006 A Coruña, Spain;
| |
Collapse
|
16
|
Ruiz-Romero C, Calamia V, Albar JP, Casal JI, Corrales FJ, Fernández-Puente P, Gil C, Mateos J, Vivanco F, Blanco FJ. The Spanish biology/disease initiative within the human proteome project: Application to rheumatic diseases. J Proteomics 2015; 127:406-13. [PMID: 25686859 DOI: 10.1016/j.jprot.2015.01.023] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2015] [Accepted: 01/24/2015] [Indexed: 12/22/2022]
Abstract
UNLABELLED The Spanish Chromosome 16 consortium is integrated in the global initiative Human Proteome Project, which aims to develop an entire map of the proteins encoded following a gene-centric strategy (C-HPP) in order to make progress in the understanding of human biology in health and disease (B/D-HPP). Chromosome 16 contains many genes encoding proteins involved in the development of a broad range of diseases, which have a significant impact on the health care system. The Spanish HPP consortium has developed a B/D platform with five programs focused on selected medical areas: cancer, obesity, cardiovascular, infectious and rheumatic diseases. Each of these areas has a clinical leader associated to a proteomic investigator with the responsibility to get a comprehensive understanding of the proteins encoded by Chromosome 16 genes. Proteomics strategies have enabled great advances in the area of rheumatic diseases, particularly in osteoarthritis, with studies performed on joint cells, tissues and fluids. BIOLOGICAL SIGNIFICANCE In this manuscript we describe how the Spanish HPP-16 consortium has developed a B/D platform with five programs focused on selected medical areas: cancer, obesity, cardiovascular, infectious and rheumatic diseases. Each of these areas has a clinical leader associated to a proteomic investigator with the responsibility to get a comprehensive understanding of the proteins encoded by Chromosome 16 genes. We show how the Proteomic strategy has enabled great advances in the area of rheumatic diseases, particularly in osteoarthritis, with studies performed on joint cells, tissues and fluids. This article is part of a Special Issue entitled: HUPO 2014.
Collapse
Affiliation(s)
- Cristina Ruiz-Romero
- Rheumatology Division, ProteoRed/ISCIII Proteomics Group, INIBIC - Hospital Universitario de A Coruña, 15006 A Coruña, Spain; CIBER-BBN Instituto de Salud Carlos III, INIBIC-CHUAC, A Coruña, Spain
| | - Valentina Calamia
- Rheumatology Division, ProteoRed/ISCIII Proteomics Group, INIBIC - Hospital Universitario de A Coruña, 15006 A Coruña, Spain
| | - Juan Pablo Albar
- ProteoRed-ISCIII, Centro Nacional de Biotecnología - CSIC, UAM Campus Cantoblanco, Darwin, 3, 28049 Madrid, Spain
| | - José Ignacio Casal
- ProteoRed-ISCIII, Functional Proteomics, Department of Cellular and Molecular Medicine, Centro de Investigaciones Biológicas (CIB-CSIC), Ramiro de Maeztu 9, 28040 Madrid, Spain
| | - Fernando J Corrales
- ProteoRed-ISCIII, Center for Applied Medical Research (CIMA), University of Navarra, Pío XII, 55; Ed. CIMA, 31008 Pamplona, Spain
| | - Patricia Fernández-Puente
- Rheumatology Division, ProteoRed/ISCIII Proteomics Group, INIBIC - Hospital Universitario de A Coruña, 15006 A Coruña, Spain
| | - Concha Gil
- ProteoRed-ISCIII, Departamento de Microbiología II, Facultad de Farmacia, Universidad Complutense de Madrid, Plaza de Ramón y Cajal, 28040 Madrid, Spain
| | - Jesús Mateos
- Rheumatology Division, ProteoRed/ISCIII Proteomics Group, INIBIC - Hospital Universitario de A Coruña, 15006 A Coruña, Spain
| | - Fernando Vivanco
- ProteoRed-ISCIII, Department of Immunology, IIS-Fundacion Jimenez Diaz, Madrid, Spain
| | - Francisco J Blanco
- Rheumatology Division, ProteoRed/ISCIII Proteomics Group, INIBIC - Hospital Universitario de A Coruña, 15006 A Coruña, Spain; RIER-RED de Inflamación y Enfermedades Reumáticas, INIBIC-CHUAC, A Coruña, Spain.
| |
Collapse
|
17
|
Lourido L, Calamia V, Mateos J, Fernández-Puente P, Fernández-Tajes J, Blanco FJ, Ruiz-Romero C. Quantitative proteomic profiling of human articular cartilage degradation in osteoarthritis. J Proteome Res 2014; 13:6096-106. [PMID: 25383958 DOI: 10.1021/pr501024p] [Citation(s) in RCA: 59] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Osteoarthritis (OA) is the most common rheumatic pathology and is characterized primarily by articular cartilage degradation. Despite its high prevalence, there is no effective therapy to slow disease progression or regenerate the damaged tissue. Therefore, new diagnostic and monitoring tests for OA are urgently needed, which would also promote the development of alternative therapeutic strategies. In the present study, we have performed an iTRAQ-based quantitative proteomic analysis of secretomes from healthy human articular cartilage explants, comparing their protein profile to those from unwounded (early disease) and wounded (advanced disease) zones of osteoarthritic tissue. This strategy allowed us to identify a panel of 76 proteins that are distinctively released by the diseased tissue. Clustering analysis allowed the classification of proteins according to their different profile of release from cartilage. Among these proteins, the altered release of osteoprotegerin (decreased in OA) and periostin (increased in OA), both involved in bone remodelling processes, was verified in further analyses. Moreover, periostin was also increased in the synovial fluid of OA patients. Altogether, the present work provides a novel insight into the mechanisms of human cartilage degradation and a number of new cartilage-characteristic proteins with possible biomarker value for early diagnosis and prognosis of OA.
Collapse
Affiliation(s)
- Lucía Lourido
- Proteomics Group-PBR2-ProteoRed/ISCIII, Rheumatology Division, §RIER-RED de Inflamación y Enfermedades Reumáticas, ∥CIBER-BBN Instituto de Salud Carlos III, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña (UDC) , As Xubias, 84, 15006-A Coruña, Spain
| | | | | | | | | | | | | |
Collapse
|
18
|
Calamia V, Mateos J, Fernández-Puente P, Lourido L, Rocha B, Fernández-Costa C, Montell E, Vergés J, Ruiz-Romero C, Blanco FJ. A pharmacoproteomic study confirms the synergistic effect of chondroitin sulfate and glucosamine. Sci Rep 2014; 4:5069. [PMID: 24912619 PMCID: PMC5381474 DOI: 10.1038/srep05069] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2013] [Accepted: 04/22/2014] [Indexed: 02/07/2023] Open
Abstract
Osteoarthritis (OA) is the most common age-related rheumatic disease. Chondrocytes play a primary role in mediating cartilage destruction and extracellular matrix (ECM) breakdown, which are main features of the OA joint. Quantitative proteomics technologies are demonstrating a very interesting power for studying the molecular effects of some drugs currently used to treat OA patients, such as chondroitin sulfate (CS) and glucosamine (GlcN). In this work, we employed the iTRAQ (isobaric tags for relative and absolute quantitation) technique to assess the effect of CS and GlcN, both alone and in combination, in modifying cartilage ECM metabolism by the analysis of OA chondrocytes secretome. 186 different proteins secreted by the treated OA chondrocytes were identified. 36 of them presented statistically significant differences (p ≤ 0.05) between untreated and treated samples: 32 were increased and 4 decreased. The synergistic chondroprotective effect of CS and GlcN, firstly reported by our group at the intracellular level, is now demonstrated also at the extracellular level.
Collapse
Affiliation(s)
- Valentina Calamia
- 1] Servicio de Reumatología, Grupo de Proteómica, ProteoRed/ISCIII, INIBIC-Hospital Universitario A Coruña. C/As Xubias S/N. 15.006, A Coruña, Spain [2] Catedra Bioibérica-Universidade da Coruña. Hospital Universitario A Coruña. C/As Xubias S/N. 15.006, A Coruña, Spain
| | - Jesús Mateos
- Servicio de Reumatología, Grupo de Proteómica, ProteoRed/ISCIII, INIBIC-Hospital Universitario A Coruña. C/As Xubias S/N. 15.006, A Coruña, Spain
| | - Patricia Fernández-Puente
- Servicio de Reumatología, Grupo de Proteómica, ProteoRed/ISCIII, INIBIC-Hospital Universitario A Coruña. C/As Xubias S/N. 15.006, A Coruña, Spain
| | - Lucía Lourido
- Servicio de Reumatología, Grupo de Proteómica, ProteoRed/ISCIII, INIBIC-Hospital Universitario A Coruña. C/As Xubias S/N. 15.006, A Coruña, Spain
| | - Beatriz Rocha
- Servicio de Reumatología, Grupo de Proteómica, ProteoRed/ISCIII, INIBIC-Hospital Universitario A Coruña. C/As Xubias S/N. 15.006, A Coruña, Spain
| | - Carolina Fernández-Costa
- Servicio de Reumatología, Grupo de Proteómica, ProteoRed/ISCIII, INIBIC-Hospital Universitario A Coruña. C/As Xubias S/N. 15.006, A Coruña, Spain
| | - Eulalia Montell
- 1] Catedra Bioibérica-Universidade da Coruña. Hospital Universitario A Coruña. C/As Xubias S/N. 15.006, A Coruña, Spain [2] Pre-clinical R&D Area, Pharma Science Division, Bioibérica, Barcelona, Spain
| | - Josep Vergés
- 1] Catedra Bioibérica-Universidade da Coruña. Hospital Universitario A Coruña. C/As Xubias S/N. 15.006, A Coruña, Spain [2] Pre-clinical R&D Area, Pharma Science Division, Bioibérica, Barcelona, Spain
| | - Cristina Ruiz-Romero
- 1] Servicio de Reumatología, Grupo de Proteómica, ProteoRed/ISCIII, INIBIC-Hospital Universitario A Coruña. C/As Xubias S/N. 15.006, A Coruña, Spain [2] CIBER-BBN-Area de Terapia Celular. Hospital Universitario A Coruña. C/As Xubias S/N. 15.006, A Coruña, Spain
| | - Francisco J Blanco
- 1] Servicio de Reumatología, Grupo de Proteómica, ProteoRed/ISCIII, INIBIC-Hospital Universitario A Coruña. C/As Xubias S/N. 15.006, A Coruña, Spain [2] Catedra Bioibérica-Universidade da Coruña. Hospital Universitario A Coruña. C/As Xubias S/N. 15.006, A Coruña, Spain [3] Departamento de Medicina. Universidad de Santiago de Compostela. Santiago de Compostela, A Coruña, Spain [4] Red de Inflamación y Enfermedades Reumatológicas. RIER/ISCIII. Madrid. Spain
| |
Collapse
|
19
|
Calamia V, Lourido L, Mateos J, Fernández-Puente P, Fernández C, Rocha B, Blanco F, Ruiz-Romero C. SAT0574 Peptidomic Analysis of Cartilage Secretome for the Discovery of Early OA Biomarkers. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.5042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
20
|
Lourido L, Calamia V, Fernández-Puente P, Mateos J, Rocha B, Fernández-Costa C, Blanco F, Ruiz-Romero C. SAT0566 Protein Profiling of Cartilage Secretome to Identify A Novel Panel of OA Biomarkers. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.5017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
21
|
Mateos J, Pintor-Iglesias A, Fernández-Puente P, García-Camba M, Ruiz-Romero C, Doménech N, Blanco FJ. Cryoconservation of peptide extracts from trypsin digestion of proteins for proteomic analysis in a hospital biobank facility. J Proteome Res 2014; 13:1930-7. [PMID: 24521361 DOI: 10.1021/pr401046u] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
We tested a semiautomated protocol for the proper storage and conservation in a hospital biobank of tryptic peptide extracts coming from samples with low and high protein complexity for subsequent mass spectrometry analysis. Low-complexity samples (serum albumin, serotransferrin. and alpha-S1-casein) were loaded in replicates in SDS-PAGE and subjected to standard in-gel trypsin digestion. For LC-MALDI-TOF/TOF analysis, purified β-galactosidase and human serum samples were in-solution digested following standard procedures and desalted with C18 stage-tips. In both cases, peptides extracts were aliquoted in individually 2D coded tubes, vacuum-dried, barcode-read, and stored in an automated -20 °C freezer in the Biobank facility. Samples were kept dried at -20 °C until the corresponding time-point of analysis, then reconstituted in the proper buffer and analyzed by either MALDI-TOF/TOF (peptide fingerprinting and MS/MS) or LC-MALDI-TOF/TOF following a highly reproducible pattern to ensure the reproducibility of the results. Protein identification was done with either Mascot or Protein Pilot as search engines using constant parameters. Over a period of 1 year we checked six different time points at days 0, 7, 30, 90, 180, and 365. We compared MS and MS/MS protein score, number of identified peptides, and coverage of the identified proteins. In the low complexity samples, the number of peptides detected gradually decreased over time, especially affecting the MS score. However, two of the three proteins - serum albumin and serotransferrin - were identified by both PMF and MS/MS at day 90. By day 180, only MS/MS identification in some replicates was possible. By LC-MS/MS, β-galactosidase and the most abundant serum proteins were identified with good scores at all time points even by day 365, with no detectable peptide loss or decrease in the fragmentation efficiency, although a progressive decrease in peptide intensity indicates that detection of low abundant proteins could not be optimal after very long periods of time. Our results encourage us to use the biobank facility in the future for long-term storage - up to 3 months - of dried peptide extracts.
Collapse
Affiliation(s)
- Jesús Mateos
- Rheumatology Division, Proteomics Unit-ProteoRed/ISCIII, INIBIC-Hospital Universitario A Coruña , As Xubias 84, 15006 A Coruña, Spain
| | | | | | | | | | | | | |
Collapse
|
22
|
Abstract
Automated liquid chromatography tandem mass spectrometry (LC-MS/MS) is a well-established technique for identification of components from complex mixtures in shotgun proteomics experiments. Approaches involving the use of matrix-assisted laser desorption/ionization mass spectrometry (LC-MALDI-MS/MS) comprise the preparation of protein extracts, their enzymatic digestion, the separation of the resulting peptides by nanoscale liquid chromatography coupled to a collector that deposits the microfractions onto a MALDI plate, and finally the mass spectrometry analysis of the fractions. Using an LC-MALDI strategy, the rate of the collection of MS/MS data is decoupled from the chromatographic separation, thus allowing high-quality data which are often complementary to electrospray ionization (LC-ESI-MS/MS) techniques.
Collapse
Affiliation(s)
- Patricia Fernández-Puente
- Rheumatology Division, ProteoRed/ISCIII Proteomics Group INIBIC - Hospital Universitario de A Coruña, A Coruña, Spain
| | | | | | | |
Collapse
|
23
|
Gayoso CM, Mateos J, Méndez JA, Fernández-Puente P, Rumbo C, Tomás M, Martínez de Ilarduya O, Bou G. Molecular mechanisms involved in the response to desiccation stress and persistence in Acinetobacter baumannii. J Proteome Res 2013; 13:460-76. [PMID: 24299215 DOI: 10.1021/pr400603f] [Citation(s) in RCA: 76] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Desiccation tolerance contributes to the maintenance of bacterial populations in hospital settings and may partly explain its propensity to cause outbreaks. Identification and relative quantitation of proteins involved in bacterial desiccation tolerance was made using label-free quantitation and iTRAQ labeling. Under desiccating conditions, the population of the Acinetobacter baumannii clinical strain AbH12O-A2 decreased in the first week, and thereafter, a stable population of 0.5% of the original population was maintained. Using label-free quantitation and iTRAQ labeling, 727 and 765 proteins, respectively, were detected; 584 of them by both methods. Proteins overexpressed under desiccation included membrane and periplasmic proteins. Proteins associated with antimicrobial resistance, efflux pumps, and quorum quenching were overexpressed in the samples subjected to desiccation stress. Electron microscopy revealed clear morphological differences between desiccated and control bacteria. We conclude that A. baumannii is able to survive long periods of desiccation through the presence of cells in a dormant state, via mechanisms affecting control of cell cycling, DNA coiling, transcriptional and translational regulation, protein stabilization, antimicrobial resistance, and toxin synthesis, and that a few surviving cells embedded in a biofilm matrix are able to resume growth and restore the original population in appropriate environmental conditions following a "bust-and-boom" strategy.
Collapse
Affiliation(s)
- Carmen M Gayoso
- Microbiology Division, INIBIC-Complejo Hospitalario Universitario de la Coruña , Xubias s/n, 3a Planta Ed. Sur 15006 La Coruña, Spain
| | | | | | | | | | | | | | | |
Collapse
|
24
|
Segura V, Medina-Aunon JA, Mora MI, Martínez-Bartolomé S, Abian J, Aloria K, Antúnez O, Arizmendi JM, Azkargorta M, Barceló-Batllori S, Beaskoetxea J, Bech-Serra JJ, Blanco F, Monteiro MB, Cáceres D, Canals F, Carrascal M, Casal JI, Clemente F, Colomé N, Dasilva N, Díaz P, Elortza F, Fernández-Puente P, Fuentes M, Gallardo O, Gharbi SI, Gil C, González-Tejedo C, Hernáez ML, Lombardía M, Lopez-Lucendo M, Marcilla M, Mato JM, Mendes M, Oliveira E, Orera I, Pascual-Montano A, Prieto G, Ruiz-Romero C, Sánchez del Pino MM, Tabas-Madrid D, Valero ML, Vialas V, Villanueva J, Albar JP, Corrales FJ. Surfing transcriptomic landscapes. A step beyond the annotation of chromosome 16 proteome. J Proteome Res 2013; 13:158-72. [PMID: 24138474 DOI: 10.1021/pr400721r] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
The Spanish team of the Human Proteome Project (SpHPP) marked the annotation of Chr16 and data analysis as one of its priorities. Precise annotation of Chromosome 16 proteins according to C-HPP criteria is presented. Moreover, Human Body Map 2.0 RNA-Seq and Encyclopedia of DNA Elements (ENCODE) data sets were used to obtain further information relative to cell/tissue specific chromosome 16 coding gene expression patterns and to infer the presence of missing proteins. Twenty-four shotgun 2D-LC-MS/MS and gel/LC-MS/MS MIAPE compliant experiments, representing 41% coverage of chromosome 16 proteins, were performed. Furthermore, mapping of large-scale multicenter mass spectrometry data sets from CCD18, MCF7, Jurkat, and Ramos cell lines into RNA-Seq data allowed further insights relative to correlation of chromosome 16 transcripts and proteins. Detection and quantification of chromosome 16 proteins in biological matrices by SRM procedures are also primary goals of the SpHPP. Two strategies were undertaken: one focused on known proteins, taking advantage of MS data already available, and the second, aimed at the detection of the missing proteins, is based on the expression of recombinant proteins to gather MS information and optimize SRM methods that will be used in real biological samples. SRM methods for 49 known proteins and for recombinant forms of 24 missing proteins are reported in this study.
Collapse
Affiliation(s)
- Víctor Segura
- ProteoRed-ISCIII, Center for Applied Medical Research (CIMA), University of Navarra , Pío XII, 55; Ed. CIMA, 31008 Pamplona, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Fernández-Puente P, Lourido L, Calamia V, Mateos J, Ruiz-Romero C, Lotz M, Blanco F. THU0021 Cartilage zone specific proteins: A quantitative proteomic analysis. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.1986] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
26
|
Rocha B, Calamia V, Mateos J, Fernández-Puente P, Lourido L, Fernández-Costa C, Fernández-Lόpez C, Oreiro N, Ruiz-Romero C, Blanco F. THU0024 Differences between healthy and osteoarthritis proteomic profiles of bone marrow mesenchymal stem cells undergoing chondrogenesis. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.1989] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
27
|
Calamia V, Mateos J, Fernández-Puente P, Lourido L, Montell E, Vergés J, Ruiz-Romero C, Blanco F. AB0121 A novel pharmacoproteomic study confirms the synergistic chondroprotective effect of chondrotin sulfate and glucosamine hydrochloride. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
28
|
Rocha B, Calamia V, Mateos J, Fernández-Puente P, Blanco FJ, Ruiz-Romero C. Metabolic labeling of human bone marrow mesenchymal stem cells for the quantitative analysis of their chondrogenic differentiation. J Proteome Res 2012; 11:5350-61. [PMID: 22989065 DOI: 10.1021/pr300572r] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Human mesenchymal stem cells (hMSCs), residing in bone marrow as well as in the synovial lining of joints, can be triggered to differentiate toward chondrocytes. Thus, hMSCs harbor great therapeutic potential for the repair of cartilage defects in osteoarthritis (OA) and other articular diseases. However, the molecular mechanisms underlying the chondrogenesis process are still in part unknown. In this work, we applied for the first time the stable isotope labeling by amino acids in cell culture (SILAC) technique for the quantitative analysis of protein modulation during the chondrogenic differentiation process of hMSCs. First, we have standardized the metabolic labeling procedure on MSCs isolated from bone marrow (hBMSCs), and we have assessed the quality of chondrogenesis taking place in these conditions. Then, chondrogenic differentiation was induced on these labeled cells, and a quantitative proteomics approach has been followed to evaluate protein changes between two differentiation days. With this strategy, we could identify 622 different proteins by LC-MALDI-TOF/TOF analysis and find 65 proteins whose abundance was significantly modulated between day 2 and day 14 of chondrogenesis. Immunohistochemistry analyses were performed to verify the changes on a panel of six proteins that play different biological roles in the cell: fibronectin, gelsolin, vimentin, alpha-ATPase, mitochondrial superoxide dismutase, and cyclophilin A. All of these proteins were increased at day 14 compared to day 2 of chondrogenic induction, thus being markers of the enhanced extracellular matrix synthesis, cell adhesion, metabolism, and response to stress processes that take place in the early steps of chondrogenesis. Our strategy has allowed an additional insight into both specific protein function and the mechanisms of chondrogenesis and has provided a panel of protein markers of this differentiation process in hBMSCs.
Collapse
Affiliation(s)
- Beatriz Rocha
- Rheumatology Division, ProteoRed/ISCIII Proteomics Group, INIBIC-Hospital Universitario de A Coruña, 15006-A Coruña, Spain
| | | | | | | | | | | |
Collapse
|
29
|
Calamia V, Lourido L, Fernández-Puente P, Mateos J, Rocha B, Montell E, Vergés J, Ruiz-Romero C, Blanco FJ. Secretome analysis of chondroitin sulfate-treated chondrocytes reveals anti-angiogenic, anti-inflammatory and anti-catabolic properties. Arthritis Res Ther 2012; 14:R202. [PMID: 23031212 PMCID: PMC3580514 DOI: 10.1186/ar4040] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2012] [Accepted: 10/02/2012] [Indexed: 02/06/2023] Open
Abstract
INTRODUCTION Chondroitin sulfate (CS) is a symptomatic slow-acting drug for osteoarthritis (OA) widely used in the clinic. The aim of this work is to find proteins whose secretion from cartilage cells under proinflammatory stimuli (IL-1β) is regulated by CS, employing a novel quantitative proteomic approach. METHODS Human articular chondrocytes released from three normal cartilages were grown in SILAC medium. When complete incorporation of the heavy isotope was achieved, chondrocytes were stimulated with IL-1β 5 ng/ml with or without CS pretreatment (200 µg/ml). Forty-eight hours later, chondrocyte secretomes were analyzed by nano-scale liquid chromatography-mass spectrometry. Real-time PCR, western blot and immunohistochemistry analyses were employed to confirm some of the results. RESULTS We could identify 75 different proteins in the secretome of human articular chondrocytes. Eighteen of these were modulated by CS with statistical significance (six increased and 12 decreased). In normal chondrocytes stimulated with IL-1β, CS reduces inflammation directly by decreasing the presence of several complement components (CFAB, C1S, CO3, and C1R) and also indirectly by increasing proteins such as TNFα-induced protein (TSG6). TSG6 overexpression correlates with a decrease in pro-matrix metalloproteinase activation (observed in MMP1 and MMP3 levels). Finally, we observed a strong CS-dependent increase of an angiogenesis inhibitor, thrombospondin-1. CONCLUSION We have generated a quantitative profile of chondrocyte extracellular protein changes driven by CS in the presence of IL-1β. We have also provided novel evidences of its anti-angiogenic, anti-inflammatory, and anti-catabolic properties. Demonstration of the anti-angiogenic action of CS might provide a novel therapeutic approach for OA targeting.
Collapse
|
30
|
Fernández-Costa C, Calamia V, Fernández-Puente P, Capelo-Martínez JL, Ruiz-Romero C, Blanco FJ. Sequential depletion of human serum for the search of osteoarthritis biomarkers. Proteome Sci 2012; 10:55. [PMID: 22971006 PMCID: PMC3515479 DOI: 10.1186/1477-5956-10-55] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2012] [Accepted: 09/06/2012] [Indexed: 12/20/2022] Open
Abstract
Background The field of biomarker discovery, development and application has been the subject of intense interest and activity, especially with the recent emergence of new technologies, such as proteomics-based approaches. In proteomics, search for biomarkers in biological fluids such as human serum is a challenging issue, mainly due to the high dynamic range of proteins present in these types of samples. Methods for reducing the content of most highly abundant proteins have been developed, including immunodepletion or protein equalization. In this work, we report for the first time the combination of a chemical sequential depletion method based in two protein precipitations with acetonitrile and DTT, with a subsequent two-dimensional difference in-gel electrophoresis (2D-DIGE) analysis for the search of osteoarthritis (OA) biomarkers in human serum. The depletion method proposed is non-expensive, of easy implementation and allows fast sample throughput. Results Following this workflow, we have compared sample pools of human serum obtained from 20 OA patients and 20 healthy controls. The DIGE study led to the identification of 16 protein forms (corresponding to 14 different proteins) that were significantly (p < 0.05) altered in OA when compared to controls (8 increased and 7 decreased). Immunoblot analyses confirmed for the first time the increase of an isoform of Haptoglobin beta chain (HPT) in sera from OA patients. Conclusions Altogether, these data demonstrate the utility of the proposed chemical sequential depletion for the analysis of sera in protein biomarker discovery approaches, exhibit the usefulness of quantitative 2D gel-based strategies for the characterization of disease-specific patterns of protein modifications, and also provide a list of OA biomarker candidates for validation.
Collapse
Affiliation(s)
- Carolina Fernández-Costa
- Rheumatology Division, ProteoRed/ISCIII Proteomics Group, INIBIC - Hospital Universitario de A Coruña, 15006, A Coruña, Spain.
| | | | | | | | | | | |
Collapse
|
31
|
Mateos J, Lourido L, Fernández-Puente P, Calamia V, Fernández-López C, Oreiro N, Ruiz-Romero C, Blanco FJ. Differential protein profiling of synovial fluid from rheumatoid arthritis and osteoarthritis patients using LC-MALDI TOF/TOF. J Proteomics 2012; 75:2869-78. [PMID: 22245418 DOI: 10.1016/j.jprot.2011.12.042] [Citation(s) in RCA: 93] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2011] [Revised: 12/27/2011] [Accepted: 12/28/2011] [Indexed: 01/05/2023]
Abstract
The purpose of this study was to identify those proteins relatively more abundant in the synovial fluid (SF) of patients suffering from rheumatoid arthritis (RA) and osteoarthritis (OA) using high performance liquid chromatography coupled to mass spectrometry. 20 individual SF samples from each disease were pooled into two groups (RA and OA) to reduce the contribution of extreme individual values. Prior to the proteomic analysis, samples were immunodepleted from the top 20 most abundant plasma proteins, to enrich the lower-abundance protein fractions. Then, they were subjected to protein size fractioning and in-gel digestion, followed by reversed-phase peptide separation in a nano-LC system and subsequent peptide identification by MALDI-TOF/TOF. This strategy led to the identification of 136 different proteins in SF, which is the largest number of SF proteins described up to date by proteomics. A relative quantification of the proteins between RA and OA was carried out by spectral counting analysis. In RA, our results show a greater relative abundance of proteins related to complement activation, inflammation and the immune response, such as the major matrix metalloproteinases and several neutrophil-related proteins. In OA, we detected an increase in proteins involved in the formation and remodeling of the extracellular matrix (ECM), such as fibronectin, kininogen-1, cartilage acidic protein 1 and cartilage oligomeric matrix protein. The results obtained for MMP-1, BGH3, fibronectin and gelsolin were verified by immunoblotting analyses. Some of the novel proteins identified in this work might be relevant not only for increasing knowledge on the etiopathogenesis of RA and OA processes, but also as putative disease biomarkers, as their presence in SF is a prior step to their dilution in serum. This article is part of a Special Issue entitled: Proteomics: The clinical link.
Collapse
Affiliation(s)
- Jesús Mateos
- Rheumatology Division, ProteoRed/ISCIII Proteomics Group, INIBIC-Hospital, Universitario de A Coruña, 15006-A Coruña, Spain
| | | | | | | | | | | | | | | |
Collapse
|
32
|
Calamia V, Fernández-Puente P, Mateos J, Lourido L, Rocha B, Montell E, Vergés J, Ruiz-Romero C, Blanco FJ. Pharmacoproteomic study of three different chondroitin sulfate compounds on intracellular and extracellular human chondrocyte proteomes. Mol Cell Proteomics 2011; 11:M111.013417. [PMID: 22203690 DOI: 10.1074/mcp.m111.013417] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Chondroitin sulfate (CS) is a symptomatic slow acting drug for osteoarthritis (OA) widely used for the treatment of this highly prevalent disease, characterized by articular cartilage degradation. However, little is known about its mechanism of action, and recent large scale clinical trials have reported variable results on OA symptoms. Herein, we aimed to study the modulations in the intracellular proteome and the secretome of human articular cartilage cells (chondrocytes) treated with three different CS compounds, with different origin or purity, by two complementary proteomic approaches. Osteoarthritic cells were treated with 200 μg/ml of each brand of CS. Quantitative proteomics experiments were carried out by the DIGE and stable isotope labeling with amino acids in cell culture (SILAC) techniques, followed by LC-MALDI-MS/MS analysis. The DIGE study, carried out on chondrocyte whole cell extracts, led to the detection of 46 spots that were differential between conditions in our study: 27 were modulated by CS1, 4 were modulated by CS2, and 15 were modulated by CS3. The SILAC experiment, carried out on the subset of chondrocyte-secreted proteins, allowed us to identify 104 different proteins. Most of them were extracellular matrix components, and 21 were modulated by CS1, 13 were modulated by CS2, and 9 were modulated by CS3. Each of the studied compounds induces a characteristic protein profile in OA chondrocytes. CS1 displayed the widest effect but increased the mitochondrial superoxide dismutase, the cartilage oligomeric matrix protein, and some catabolic or inflammatory factors like interstitial collagenase, stromelysin-1, and pentraxin-related protein. CS2 and CS3, on the other hand, increased a number of structural proteins, growth factors, and extracellular matrix proteins. Our study shows how, from the three CS compounds tested, CS1 induces the activation of inflammatory and catabolic pathways, whereas CS2 and CS3 induce an anti-inflammatory and anabolic response. The data presented emphasize the importance of employing high quality CS compounds, supported by controlled clinical trials, in the therapy of OA. Finally, the present work exemplifies the usefulness of proteomic approaches in pharmacological studies.
Collapse
Affiliation(s)
- Valentina Calamia
- Osteoarticular and Aging Research Lab, Proteomics Unit, ProteoRed/ISCIII, Rheumatology Division, INIBIC-CHU A Coruña, As Xubias 84, 15006 A Coruña, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Fernández-Puente P, Mateos J, Fernández-Costa C, Oreiro N, Fernández-López C, Ruiz-Romero C, Blanco FJ. Identification of a panel of novel serum osteoarthritis biomarkers. J Proteome Res 2011; 10:5095-101. [PMID: 21973172 DOI: 10.1021/pr200695p] [Citation(s) in RCA: 78] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Osteoarthritis (OA) is the most common rheumatic pathology. Because currently available diagnostic methods are limited and lack sensitivity, the identification of new specific biological markers for OA has become a focus. The purpose of this study was to identify novel protein biomarkers for moderate and severe OA in serum. Sera were obtained from 50 moderate OA patients, 50 severe OA patients, and 50 nonsymptomatic controls. Serum protein levels were analyzed using isobaric tags for relative and absolute quantitation (iTRAQ) and matrix-assisted laser desorption/ionization (MALDI)-TOF/TOF mass spectrometry. We identified 349 different proteins in the sera, 262 of which could be quantified by calculation of their iTRAQ ratios. Three sets of proteins were significantly (p < 0.05) changed in OA samples compared to controls. Of these, 6 were modulated only in moderate OA, 13 only in severe OA and 7 in both degrees. Although some of these proteins, such as cartilage oligomeric matrix protein, have a previously reported putative biomarker value for OA, most are novel biomarker candidates for the disease. These include some complement components, lipoproteins, von Willebrand factor, tetranectin, and lumican. The specificity and selectivity of these candidates need to be validated before new molecular diagnostic or prognostic tests for OA can be developed.
Collapse
|
34
|
Rodríguez-Rigueiro T, Valladares-Ayerbes M, Haz-Conde M, Blanco M, Aparicio G, Fernández-Puente P, Blanco FJ, Lorenzo MJ, Aparicio LA, Figueroa A. A novel procedure for protein extraction from formalin-fixed paraffin-embedded tissues. Proteomics Clin Appl 2011. [DOI: 10.1002/prca.201190092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
35
|
Calamia V, Rocha B, Mateos J, Fernández-Puente P, Ruiz-Romero C, Blanco FJ. Metabolic labeling of chondrocytes for the quantitative analysis of the interleukin-1-beta-mediated modulation of their intracellular and extracellular proteomes. J Proteome Res 2011; 10:3701-11. [PMID: 21692455 DOI: 10.1021/pr200331k] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Chondrocytes are widely used as an in vitro model of cartilage diseases such as osteoarthritis (OA). As the unique residents of mature cartilage, they are responsible of the synthesis and release of proteins essential for a proper tissue turnover. In this work, the stable isotope labeling with amino acids in cell culture (SILAC) technique has been standardized in primary human articular chondrocytes (HACs) for quantitative proteomic analyses. Then, it has been employed to study those protein modifications caused by the proinflammatory cytokine Interleukin-1beta (IL-1β), a well-known OA mediator, in these cells. Quantitative analysis of the IL-1β-treated HACs proteome revealed a global increase in cellular chaperones concurrent with a down-regulation of the actin cytoskeleton. HACs secretome analysis led to the identification and quantification of 115 proteins and unveiled the effects of the cytokine on the cartilage extracellular matrix metabolism. Among those modulated proteins, three protein clusters were found to be remarkably increased by IL-1β: proinflammatory mediators and proteases, type VI collagen and proteins known to bind this molecule, and proteins related with the TGF-beta pathway. On the other hand, secretion of aggrecan, two vitamin K-dependent proteins, and thrombospondin, among others, was strongly reduced. Altogether, these data demonstrate the usefulness of metabolic labeling for quantitative proteomics studies in HACs, show the complementarity of intracellular proteome and secretome analyses, and provide a comprehensive study of the IL-1β-mediated effects on these cells. Proteins identified in the secretome approach have a potential use as biomarkers or therapeutic targets for OA.
Collapse
Affiliation(s)
- Valentina Calamia
- Unidad de Investigación del Envejecimiento Osteoarticular INIBIC-Complejo Hospitalario Universitario A Coruña, A Coruña, Spain
| | | | | | | | | | | |
Collapse
|
36
|
Rodríguez-Rigueiro T, Valladares-Ayerbes M, Haz-Conde M, Blanco M, Aparicio G, Fernández-Puente P, Blanco FJ, Lorenzo MJ, Aparicio LA, Figueroa A. A novel procedure for protein extraction from formalin-fixed paraffin-embedded tissues. Proteomics 2011; 11:2555-9. [PMID: 21591256 DOI: 10.1002/pmic.201000809] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2010] [Revised: 02/28/2011] [Accepted: 03/22/2011] [Indexed: 01/25/2023]
Abstract
Most of the archived pathological specimens in hospitals are kept as formalin-fixed paraffin-embedded tissues (FFPE) for long-term preservation. Up to now, these samples are only used for immunohistochemistry in a clinical routine as it is difficult to recover intact protein from these FFPE tissues. Here, we report a novel, short time-consuming and cost-effective method to extract full-length, non-degraded proteins from FFPE tissues. This procedure is combined with an effective and non-toxic deparaffinisation process and an extraction method based on antigen-retrieval, high concentration of SDS and high temperature. We have obtained enough intact protein to be detected by Western blotting analysis. This technique will allow utilising these stored FFPE tissues in several applications for protein analysis helping to advance the translational studies in cancer and other diseases.
Collapse
Affiliation(s)
- Teresa Rodríguez-Rigueiro
- Translational Cancer Research Group, Proteo-Red-ISCIII, Instituto de Investigación Biomédica A Coruña, Coruña, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Calamia V, Ruiz-Romero C, Rocha B, Fernández-Puente P, Mateos J, Montell E, Vergés J, Blanco FJ. Pharmacoproteomic study of the effects of chondroitin and glucosamine sulfate on human articular chondrocytes. Arthritis Res Ther 2010; 12:R138. [PMID: 20626852 PMCID: PMC2945029 DOI: 10.1186/ar3077] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2010] [Revised: 06/20/2010] [Accepted: 07/13/2010] [Indexed: 02/06/2023] Open
Abstract
Introduction Chondroitin sulfate (CS) and glucosamine sulfate (GS) are symptomatic slow-acting drugs for osteoarthritis (OA) widely used in clinic. Despite their widespread use, knowledge of the specific molecular mechanisms of their action is limited. The aim of this work is to explore the utility of a pharmacoproteomic approach for the identification of specific molecules involved in the pharmacological effect of GS and CS. Methods Chondrocytes obtained from three healthy donors were treated with GS 10 mM and/or CS 200 μg/mL, and then stimulated with interleukin-1β (IL-1β) 10 ng/mL. Whole cell proteins were isolated 24 hours later and resolved by two-dimensional electrophoresis. The gels were stained with SYPRORuby. Modulated proteins were identified by matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF/TOF) mass spectrometry. Real-time PCR and Western blot analyses were performed to validate our results. Results A total of 31 different proteins were altered by GS or/and CS treatment when compared to control. Regarding their predicted biological function, 35% of the proteins modulated by GS are involved in signal transduction pathways, 15% in redox and stress response, and 25% in protein synthesis and folding processes. Interestingly, CS affects mainly energy production (31%) and metabolic pathways (13%), decreasing the expression levels of ten proteins. The chaperone GRP78 was found to be remarkably increased by GS alone and in combination with CS, a fact that unveils a putative mechanism for the reported anti-inflammatory effect of GS in OA. On the other hand, the antioxidant enzyme superoxide dismutase 2 (SOD2) was significantly decreased by both drugs and synergistically by their combination, thus suggesting a drug-induced decrease of the oxidative stress caused by IL-1β in chondrocytes. Conclusions CS and GS differentially modulate the proteomic profile of human chondrocytes. This pharmacoproteomic approach unravels the complex intracellular mechanisms that are modulated by these drugs on IL1β-stimulated human articular chondrocytes.
Collapse
Affiliation(s)
- Valentina Calamia
- Rheumatology Division, INIBIC-CHU A Coruña, As Xubias s/n, A Coruña 15006, Spain.
| | | | | | | | | | | | | | | |
Collapse
|
38
|
Ruiz-Romero C, Calamia V, Rocha B, Mateos J, Fernández-Puente P, Blanco FJ. Hypoxia Conditions Differentially Modulate Human Normal and Osteoarthritic Chondrocyte Proteomes. J Proteome Res 2010; 9:3035-45. [DOI: 10.1021/pr901209s] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Affiliation(s)
- Cristina Ruiz-Romero
- Unidad de Investigación del Envejecimiento Osteoarticular, INIBIC-Complejo Hospitalario Universitario A Coruña, Spain
| | - Valentina Calamia
- Unidad de Investigación del Envejecimiento Osteoarticular, INIBIC-Complejo Hospitalario Universitario A Coruña, Spain
| | - Beatriz Rocha
- Unidad de Investigación del Envejecimiento Osteoarticular, INIBIC-Complejo Hospitalario Universitario A Coruña, Spain
| | - Jesús Mateos
- Unidad de Investigación del Envejecimiento Osteoarticular, INIBIC-Complejo Hospitalario Universitario A Coruña, Spain
| | - Patricia Fernández-Puente
- Unidad de Investigación del Envejecimiento Osteoarticular, INIBIC-Complejo Hospitalario Universitario A Coruña, Spain
| | - Francisco J. Blanco
- Unidad de Investigación del Envejecimiento Osteoarticular, INIBIC-Complejo Hospitalario Universitario A Coruña, Spain
| |
Collapse
|